Sandra Herranz-Antolín
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sandra Herranz-Antolín has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Tejera-Pérez
Department of Endocrinology and Nutrition, University Hospital Complex of Ferrol, A Coruña, Spain; Epigenomics Group in Endocrinology and Nutrition, Epigenomics Unit, Health Research Institute of Santiago de Compostela, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain
3 shared publications Gema López-Gallardo
Virgen del Rocío University Hospital, Sevilla, Spain
3 shared publicationsJavier González-López
Sección de Endocrinología y Nutrición, Hospital Virgen de la Luz, Cuenca, Spain
3 shared publicationsJulia Sastre
Servicio de Endocrinología y Nutrición, Complejo Hospitalario Universitario de Toledo, Toledo, Spain
3 shared publicationsMaría Covadonga López-Virgos
Internal Medicine Department, University Hospital of Guadalajara, Guadalajara, Spain
3 shared publicationsMiguel Torralba
Instituto de Investigación Sanitaria de Castilla La Mancha (IDISCAM), Toledo, Spain
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Association Between the GMI / HbA1c Ratio and Microvascular Complications in Type 1 Diabetes: A Multicenter Cross‐Sectional Study
Objective: To clarify whether the glucose management indicator (GMI)/glycated haemoglobin (HbA1c) ratio (GMI/HbA1c ratio) is an independent predictor of microvascular complications in Type 1 diabetes (T1D). Design and Methods: Multicentre, cross‐sectional, observational study including subjects with T1D with at least 5 years of evolution, users of continuous glucose monitoring (CGM) with a coverage ≥ 80% 56 days prior to HbA1c. Logistic regression models were used to identify the factors independently associated with grouped microvascular complications and ocular disease. Results: As per data, 1315 participants were included. Patients were classified into tertiles based on the GMI/HbA1c ratio. High glycators were older than intermediate and low glycators (55.4 vs. 53.4 vs. 50.8 years; p < 0.001), respectively. Differences were also observed among the three groups with regard to average glucose (156.3 vs. 161.8 vs. 166.1 mg/dL; p < 0.001), time in range (66.3% vs. 62.9% vs. 59.9%; p < 0.001), time in tight range (42.9% vs. 39.9% vs. 37.1%; p < 0.001), coefficient of variation (34.5% vs. 34.9% vs. 35.6%; p = 0.023), GMI (7% vs. 7.2% vs. 7.3%; p < 0.001) and HbA1c (8.1% vs. 7.3% vs. 6.6%; p < 0.001). In the high glycators group, the prevalence of microvascular complications was higher than in the intermediate and low glycators (38.9% vs. 28.2% vs. 23.7%; p < 0.001), respectively. Also, the prevalence of ocular disease (31% vs. 20.2% vs. 19.7%; p < 0.001), nephropathy (14.9% vs. 8.3% vs. 6.2%; p < 0.001) and polyneuropathy (10.6% vs. 6.8% vs. 3.4%; p < 0.001) was higher in high glycators, The GMI/HbA1c ratio was significantly associated with the presence of grouped microvascular complications (OR 0.71; 95% CI: 0.61–0.81; p < 0.001) and ocular disease (OR 0.71; 95% CI: 0.61–0.82; p < 0.001) after adjusting for clinical ad glucometric variables. Conclusions: The GMI/HbA1c ratio is associated with microvascular complications in this study. These results highlight the potential of this parameter in routine clinical practice for stratifying the risk of complications and for establishing individualized control goals and screening strategies.
- 15 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessAssociation Between the GMI / HbA1c Ratio and Microvascular Complications in Type 1 Diabetes: A Multicenter Cross‐Sectional Study
Objective: To clarify whether the glucose management indicator (GMI)/glycated haemoglobin (HbA1c) ratio (GMI/HbA1c ratio) is an independent predictor of microvascular complications in Type 1 diabetes (T1D). Design and Methods: Multicentre, cross‐sectional, observational study including subjects with T1D with at least 5 years of evolution, users of continuous glucose monitoring (CGM) with a coverage ≥ 80% 56 days prior to HbA1c. Logistic regression models were used to identify the factors independently associated with grouped microvascular complications and ocular disease. Results: As per data, 1315 participants were included. Patients were classified into tertiles based on the GMI/HbA1c ratio. High glycators were older than intermediate and low glycators (55.4 vs. 53.4 vs. 50.8 years; p < 0.001), respectively. Differences were also observed among the three groups with regard to average glucose (156.3 vs. 161.8 vs. 166.1 mg/dL; p < 0.001), time in range (66.3% vs. 62.9% vs. 59.9%; p < 0.001), time in tight range (42.9% vs. 39.9% vs. 37.1%; p < 0.001), coefficient of variation (34.5% vs. 34.9% vs. 35.6%; p = 0.023), GMI (7% vs. 7.2% vs. 7.3%; p < 0.001) and HbA1c (8.1% vs. 7.3% vs. 6.6%; p < 0.001). In the high glycators group, the prevalence of microvascular complications was higher than in the intermediate and low glycators (38.9% vs. 28.2% vs. 23.7%; p < 0.001), respectively. Also, the prevalence of ocular disease (31% vs. 20.2% vs. 19.7%; p < 0.001), nephropathy (14.9% vs. 8.3% vs. 6.2%; p < 0.001) and polyneuropathy (10.6% vs. 6.8% vs. 3.4%; p < 0.001) was higher in high glycators, The GMI/HbA1c ratio was significantly associated with the presence of grouped microvascular complications (OR 0.71; 95% CI: 0.61–0.81; p < 0.001) and ocular disease (OR 0.71; 95% CI: 0.61–0.82; p < 0.001) after adjusting for clinical ad glucometric variables. Conclusions: The GMI/HbA1c ratio is associated with microvascular complications in this study. These results highlight the potential of this parameter in routine clinical practice for stratifying the risk of complications and for establishing individualized control goals and screening strategies.
- 28 May 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (11) , 1153-1163
Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study
Objective: To clarify the distinctions between Latent Autoimmune Diabetes in Adults (LADA) and Type 1 diabetes (T1D) diagnosed < 30 years using continuous glucose monitoring (CGM) metrics, glycation rate, and risk of complications. Design and Methods: Multicenter, cross-sectional, observational study including subjects with T1D onset < 30 years (T1D cohort) and those classified as LADA diagnosed ≥ 30 years (LADA cohort) with ≥ 80% CGM coverage 56 days prior to glycated hemoglobin (HbA1c). Logistic regression was used to model the risk of complications. Results: T1D ( n = 555) and LADA ( n = 890) showed different ages (43 vs. 58 years; P < 0.001), age at diagnosis (16 vs. 43 years; P < 0.001), diabetes duration (26.8 vs. 15.1 years; P < 0.001), HbA1c (7.2 vs. 7.3%; P = 0.017), microvascular complications (35 vs. 23%; P < 0.001), and daily total and basal insulin [0.63 vs. 0.59 U/(kg·d); P = 0.006 and 0.35 vs. 0.32 U/(kg·d); P = 0.002]. After adjusting for diabetes duration, T1D exhibited higher time below range (TBR70: 3.9 vs. 3.0%; P < 0.001; TBR54: 0.5 vs. 0.3%; P < 0.001) and variability [coefficient of variation (CV): 35.6 vs. 34.2%; P < 0.001; within-day CV: 31.4 vs. 30.3%; P < 0.001]. Personal glycation ratio was higher in LADA after adjusting for diabetes duration and body mass index (66.5 vs. 64.9%; P < 0.001). Estimated risks of macrovascular and microvascular complications were higher in LADA than in T1D [12.6% (95% CI 9.7–15) vs. 3.8% (95% CI 2.1–5.6) and 46.1% (95% CI 40.4–52.0) vs. 29.1% (95% CI 25.1–33.5)] after adjusted for diabetes duration. Conclusions: LADA cohort showed a higher glycation rate and lower time in hypoglycemia and variability. Microvascular complications were more common in T1D, but after adjusting for diabetes duration, macrovascular and microvascular risks were greater in LADA.
- 28 May 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (11) , 1153-1163
Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study
Objective: To clarify the distinctions between Latent Autoimmune Diabetes in Adults (LADA) and Type 1 diabetes (T1D) diagnosed < 30 years using continuous glucose monitoring (CGM) metrics, glycation rate, and risk of complications. Design and Methods: Multicenter, cross-sectional, observational study including subjects with T1D onset < 30 years (T1D cohort) and those classified as LADA diagnosed ≥ 30 years (LADA cohort) with ≥ 80% CGM coverage 56 days prior to glycated hemoglobin (HbA1c). Logistic regression was used to model the risk of complications. Results: T1D ( n = 555) and LADA ( n = 890) showed different ages (43 vs. 58 years; P < 0.001), age at diagnosis (16 vs. 43 years; P < 0.001), diabetes duration (26.8 vs. 15.1 years; P < 0.001), HbA1c (7.2 vs. 7.3%; P = 0.017), microvascular complications (35 vs. 23%; P < 0.001), and daily total and basal insulin [0.63 vs. 0.59 U/(kg·d); P = 0.006 and 0.35 vs. 0.32 U/(kg·d); P = 0.002]. After adjusting for diabetes duration, T1D exhibited higher time below range (TBR70: 3.9 vs. 3.0%; P < 0.001; TBR54: 0.5 vs. 0.3%; P < 0.001) and variability [coefficient of variation (CV): 35.6 vs. 34.2%; P < 0.001; within-day CV: 31.4 vs. 30.3%; P < 0.001]. Personal glycation ratio was higher in LADA after adjusting for diabetes duration and body mass index (66.5 vs. 64.9%; P < 0.001). Estimated risks of macrovascular and microvascular complications were higher in LADA than in T1D [12.6% (95% CI 9.7–15) vs. 3.8% (95% CI 2.1–5.6) and 46.1% (95% CI 40.4–52.0) vs. 29.1% (95% CI 25.1–33.5)] after adjusted for diabetes duration. Conclusions: LADA cohort showed a higher glycation rate and lower time in hypoglycemia and variability. Microvascular complications were more common in T1D, but after adjusting for diabetes duration, macrovascular and microvascular risks were greater in LADA.
- 26 August 2025
- Published by Springer Nature in Endocrine
- Vol. 90 (2) , 588-595
Time in Tight Range (TITR) stratified by Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study
Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and the relationship between TITR-Time in Range (TIR) and assess their possible differences according to Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus (DM) and Multiple Daily Injections in real life. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least one HbA1c (October 1, 2023-October 1, 2024) and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R2 Adjusted 0.89; p < 0.001) and varied according to CV [CV ≤ 36% (β = 0.88; CI 95% 0.83–0.93; R2 Adjusted 0.89; p < 0.001); CV > 36% (β = 0.84; CI 95% 0.81–0.87; R2 Adjusted 0.93; p < 0.001)]. The cutoff value for TIR to discriminate TITR ≥ 50% varied according to CV [(CV ≤ 36% 75.9% (sensitivity 98%, specificity 94%, AUC 0.99, p < 0.001); CV > 36% 70.5% (sensitivity 100%, specificity 98%, AUC 0.99, p < 0.001)]. The variables that were independently associated with TITR in CV ≤ 36% group were TIR (β = 0.74; CI 95% 0.57–0.9; p < 0.001) and mean glucose (β = −0.11; CI 95% −0.21 to −0.01; p = 0.045). However, in CV > 36% group were time of evolution (β = 0.04; CI 95% 0.01–0.07; p = 0.008), HbA1c (β = −0.63; CI 95% −1.22 to −0.4; p = 0.036; CV (β = 0.33; CI 95% 0.24–0.41; p < 0.001) and TIR (β = 0.84; CI 95% 0.74–0.93; p < 0.001). Conclusions The correlation between TITR-TIR was strong and higher in patients with CV > 36%. Cutoff value for TIR to discriminate TITR ≥ 50% and factors that were associated with TITR also differ depending on CV. It is essential to take glycemic variability into account when interpreting metabolic control data.
- 26 August 2025
- Published by Springer Nature in Endocrine
- Vol. 90 (2) , 588-595
Time in Tight Range (TITR) stratified by Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study
Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and the relationship between TITR-Time in Range (TIR) and assess their possible differences according to Coefficient of Variation (CV) in a cohort of patients with type 1 Diabetes Mellitus (DM) and Multiple Daily Injections in real life. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least one HbA1c (October 1, 2023-October 1, 2024) and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R2 Adjusted 0.89; p < 0.001) and varied according to CV [CV ≤ 36% (β = 0.88; CI 95% 0.83–0.93; R2 Adjusted 0.89; p < 0.001); CV > 36% (β = 0.84; CI 95% 0.81–0.87; R2 Adjusted 0.93; p < 0.001)]. The cutoff value for TIR to discriminate TITR ≥ 50% varied according to CV [(CV ≤ 36% 75.9% (sensitivity 98%, specificity 94%, AUC 0.99, p < 0.001); CV > 36% 70.5% (sensitivity 100%, specificity 98%, AUC 0.99, p < 0.001)]. The variables that were independently associated with TITR in CV ≤ 36% group were TIR (β = 0.74; CI 95% 0.57–0.9; p < 0.001) and mean glucose (β = −0.11; CI 95% −0.21 to −0.01; p = 0.045). However, in CV > 36% group were time of evolution (β = 0.04; CI 95% 0.01–0.07; p = 0.008), HbA1c (β = −0.63; CI 95% −1.22 to −0.4; p = 0.036; CV (β = 0.33; CI 95% 0.24–0.41; p < 0.001) and TIR (β = 0.84; CI 95% 0.74–0.93; p < 0.001). Conclusions The correlation between TITR-TIR was strong and higher in patients with CV > 36%. Cutoff value for TIR to discriminate TITR ≥ 50% and factors that were associated with TITR also differ depending on CV. It is essential to take glycemic variability into account when interpreting metabolic control data.
- 30 July 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (12) , 2137-2144
Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study
Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and assess their possible differences according to Time Below Range (TBR) in a cohort of type 1 diabetes mellitus people with Múltiple Daily Injections. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least a HbA1c during the period October 1, 2023-October 1, 2024, and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R [2] Adjusted 0.89; p < 0.001) and varied according to TBR [TBR < 4% group (β = 0.81; CI 95% 0.78 to 0.85; R [2] Adjusted 0.9; p < 0.001) vs. TBR ≥ 4% (β = 0.9; CI 95% 0.86 to 0.94; R [2] Adjusted 0.93; p < 0.001)]. The variables independently associated with TITR in patient with TBR < 4% were HbA1c (β = -9.58; CI 95% -10.88 to -8.29; p < 0.001) and Coefficient of Variation (CV) (β = -0.38; CI 95% -0.66 to -0.11; p = 0.007). However, in those with TBR ≥ 4% were male gender (β = 2.86; CI 95% 0.26 to 5.45; p = 0.031), HbA1c (β = -7.53; CI 95% -9.1 to -5.96; p < 0.001) and CV (β = -0.69; CI 95% -1.01 to -0.37; p < 0.001). Conclusions The correlation between TITR and TIR and the factors that were independently associated with TITR differ depending on the TBR.
- 30 July 2025
- Published by Springer Nature in Acta Diabetologica
- Vol. 62 (12) , 2137-2144
Time in Tight Range (TITR) stratified by Time Below Range (TBR) in a cohort of patients with type 1 Diabetes Mellitus and Multiple Daily Injections. A real-life study
Objetive To analyze the Time in Tight Range (TITR) (70–140 mg/dL) and assess their possible differences according to Time Below Range (TBR) in a cohort of type 1 diabetes mellitus people with Múltiple Daily Injections. Patients and methods 355 adult users of Continuous Glucose Monitoring (CGM) with at least a HbA1c during the period October 1, 2023-October 1, 2024, and glucose data in the 90 days prior were included. Results Age 46.9 years (SD 13.6); 57.2% male; time of evolution 21.6 years (SD 12.6). Mean TITR was 38.4% (SD 14.6) and 20.3% had a TITR ≥ 50%. The correlation TITR-TIR was strong (β = 0.83; CI 95% 0.8–0.87; R [2] Adjusted 0.89; p < 0.001) and varied according to TBR [TBR < 4% group (β = 0.81; CI 95% 0.78 to 0.85; R [2] Adjusted 0.9; p < 0.001) vs. TBR ≥ 4% (β = 0.9; CI 95% 0.86 to 0.94; R [2] Adjusted 0.93; p < 0.001)]. The variables independently associated with TITR in patient with TBR < 4% were HbA1c (β = -9.58; CI 95% -10.88 to -8.29; p < 0.001) and Coefficient of Variation (CV) (β = -0.38; CI 95% -0.66 to -0.11; p = 0.007). However, in those with TBR ≥ 4% were male gender (β = 2.86; CI 95% 0.26 to 5.45; p = 0.031), HbA1c (β = -7.53; CI 95% -9.1 to -5.96; p < 0.001) and CV (β = -0.69; CI 95% -1.01 to -0.37; p < 0.001). Conclusions The correlation between TITR and TIR and the factors that were independently associated with TITR differ depending on the TBR.
- 2 June 2025
- Published by Elsevier in Endocrinología, Diabetes y Nutrición (English Ed.)
- Vol. 72 (6) , 501580
CANTCAM project (ANaplastic Thyroid Carcinoma in CAstilla-La Mancha). Multicenter retrospective study
- 2 June 2025
- Published by Elsevier in Endocrinología, Diabetes y Nutrición (English Ed.)
- Vol. 72 (6) , 501580
CANTCAM project (ANaplastic Thyroid Carcinoma in CAstilla-La Mancha). Multicenter retrospective study
- 13 December 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (12) , 960-967
Glycemic Risk Index in a Cohort of Patients with Type 1 Diabetes Mellitus Stratified by the Coefficient of Variation: A Real-Life Study
Objective: : To analyze the Glycemic Risk Index (GRI) and assess their possible differences according to coefficient of variation (CV) in a cohort of real-life type 1 diabetes mellitus (DM) patient users of intermittently scanned continuous glucose monitoring (isCGM). Patients and Methods: : In total, 447 adult users of isCGM with an adherence ≥70% were included in a cross-sectional study. GRI was calculated with its hypoglycemia (CHypo) and hyperglycemia (CHyper) components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results: Mean age was 44.6 years (standard deviation [SD] 13.7), 57.7% being male; age of DM onset was 24.5 years (SD 14.3) and time of evolution was 20.6 years (SD 12.3). In patients with CV >36% (52.8%) versus CV ≤36% (47.2%), differences were observed in relation to GRI (18.8% [SD 1.9]; P < 0.001), CHypo (2.9% [SD 0.3]; P < 0.001), CHyper (6.3% [SD 1.4]; P < 0.001), and all classical glucometric parameters except time above range level 1. The variables that were independently associated with GRI in patient with CV >36% were time in range (TIR) (β = −1.49; confidence interval [CI:] 95% −1.63 to −1.37; P < 0.001), glucose management indicator (GMI) (β = −7.22; CI: 95% −9.53 to −4.91; P < 0.001), and CV (β = 0.85; CI: 95% 0.69 to 1.02; P < 0.001). However, in patients with CV ≤36%, the variables were age (β = 0.15; CI: 95% 0.03 to 0.28; P = 0.019), age of onset (β = −0.15; CI: 95% −0.28 to −0.02; P = 0.023), TIR (β = −1.35; CI: 95% −1.46 to −1.23; P < 0.001), GMI (β = −6.67; CI: 95% −9.18 to −4.15; P < 0.001), and CV (β = 0.33; CI: 95% 0.11 to 0.56; P = 0.004). Conclusions: In this study, the factors independently associated with metabolic control according to GRI are modified by glycemic variability.
- 13 December 2024
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (12) , 960-967
Glycemic Risk Index in a Cohort of Patients with Type 1 Diabetes Mellitus Stratified by the Coefficient of Variation: A Real-Life Study
Objective: : To analyze the Glycemic Risk Index (GRI) and assess their possible differences according to coefficient of variation (CV) in a cohort of real-life type 1 diabetes mellitus (DM) patient users of intermittently scanned continuous glucose monitoring (isCGM). Patients and Methods: : In total, 447 adult users of isCGM with an adherence ≥70% were included in a cross-sectional study. GRI was calculated with its hypoglycemia (CHypo) and hyperglycemia (CHyper) components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results: Mean age was 44.6 years (standard deviation [SD] 13.7), 57.7% being male; age of DM onset was 24.5 years (SD 14.3) and time of evolution was 20.6 years (SD 12.3). In patients with CV >36% (52.8%) versus CV ≤36% (47.2%), differences were observed in relation to GRI (18.8% [SD 1.9]; P < 0.001), CHypo (2.9% [SD 0.3]; P < 0.001), CHyper (6.3% [SD 1.4]; P < 0.001), and all classical glucometric parameters except time above range level 1. The variables that were independently associated with GRI in patient with CV >36% were time in range (TIR) (β = −1.49; confidence interval [CI:] 95% −1.63 to −1.37; P < 0.001), glucose management indicator (GMI) (β = −7.22; CI: 95% −9.53 to −4.91; P < 0.001), and CV (β = 0.85; CI: 95% 0.69 to 1.02; P < 0.001). However, in patients with CV ≤36%, the variables were age (β = 0.15; CI: 95% 0.03 to 0.28; P = 0.019), age of onset (β = −0.15; CI: 95% −0.28 to −0.02; P = 0.023), TIR (β = −1.35; CI: 95% −1.46 to −1.23; P < 0.001), GMI (β = −6.67; CI: 95% −9.18 to −4.15; P < 0.001), and CV (β = 0.33; CI: 95% 0.11 to 0.56; P = 0.004). Conclusions: In this study, the factors independently associated with metabolic control according to GRI are modified by glycemic variability.
- Open Access
- 3 December 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 44, 155-164
Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial
- 3 December 2024
- Published by Elsevier in Clinical Nutrition
- Vol. 44, 155-164
Open AccessBiomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial
- 6 June 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (2) , 574-583
Factors associated with Glycemia Risk Index in a cohort of patients with type 1 Diabetes Mellitus and Latent Autoimmune Diabetes In Adults (LADA)
Objective To analyze the degree of control based on classical glucometric parameters and Glycemia Risk Index (GRI) in real-life conditions in a cohort of patients with type 1 Diabetes Mellitus (DM) and Latent Autoimmune Diabetes in Adults (LADA) and to assess the factors that are associated with GRI. Patients and methods Cross-sectional study. 447 adult patients with type 1 DM and LADA users of Intermittent Continuous Glucose Monitoring (iCGM) with an adherence ≥ 70% were included. GRI was calculated with its Hypoglycemia (CHypo) and Hyperglycemia (CHyper) Components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results Mean age 44.6 years (SD 13.7); 57.7% men; 83.9% type 1 DM; 16.1% LADA; time of evolution 20.6 years (SD 12.3). In patients with type 1 DM vs. LADA, differences were observed in relation to age [−11.1 years (SD 1.7)], age of onset [−21.9 years (DE 1.5)], time of evolution [11.7 years (DE 1.5)], treatment modality (p < 0.001), Time in Range (TIR) [−6.3% (SD 2.2)], Time Below Range (TBR) [1.9% (SD 0.6)], TBR level 1 (TBR1) [1.4% (SD 0.5)], Time Above Range (TAR) level 2 (TAR2) [4.7% (SD 1.3)], Coefficient of Variation (CV) [4.6% (SD 0.9)], GRI [11.3% (SD 2.8)], CHypo [1.3% (SD 0.5)] and CHyper [4.8% (SD 1.7)]. The variables that were independently associated with GRI were TIR (β = −1.34; CI 95% −1.43 to −1.25; p < 0.001), Glucose Management Indicator (GMI) (β = −5.82; CI 95% −7.59 to −4.05; p < 0.001), CV (β = 0.67; CI 95% 0.57 to 0.77; p < 0.001) and adherence to sensor usage (β = −0.16; CI 95% −1.27 to −0.06; p < 0.002). Conclusions LADA present better control according to some glucometric parameters and a low GRI. However, the type of DM is not a factor that is independently associated with GRI.
- 6 June 2024
- Published by Springer Nature in Endocrine
- Vol. 86 (2) , 574-583
Factors associated with Glycemia Risk Index in a cohort of patients with type 1 Diabetes Mellitus and Latent Autoimmune Diabetes In Adults (LADA)
Objective To analyze the degree of control based on classical glucometric parameters and Glycemia Risk Index (GRI) in real-life conditions in a cohort of patients with type 1 Diabetes Mellitus (DM) and Latent Autoimmune Diabetes in Adults (LADA) and to assess the factors that are associated with GRI. Patients and methods Cross-sectional study. 447 adult patients with type 1 DM and LADA users of Intermittent Continuous Glucose Monitoring (iCGM) with an adherence ≥ 70% were included. GRI was calculated with its Hypoglycemia (CHypo) and Hyperglycemia (CHyper) Components. Multivariate linear regression analysis was performed to evaluate the factors associated with GRI. Results Mean age 44.6 years (SD 13.7); 57.7% men; 83.9% type 1 DM; 16.1% LADA; time of evolution 20.6 years (SD 12.3). In patients with type 1 DM vs. LADA, differences were observed in relation to age [−11.1 years (SD 1.7)], age of onset [−21.9 years (DE 1.5)], time of evolution [11.7 years (DE 1.5)], treatment modality (p < 0.001), Time in Range (TIR) [−6.3% (SD 2.2)], Time Below Range (TBR) [1.9% (SD 0.6)], TBR level 1 (TBR1) [1.4% (SD 0.5)], Time Above Range (TAR) level 2 (TAR2) [4.7% (SD 1.3)], Coefficient of Variation (CV) [4.6% (SD 0.9)], GRI [11.3% (SD 2.8)], CHypo [1.3% (SD 0.5)] and CHyper [4.8% (SD 1.7)]. The variables that were independently associated with GRI were TIR (β = −1.34; CI 95% −1.43 to −1.25; p < 0.001), Glucose Management Indicator (GMI) (β = −5.82; CI 95% −7.59 to −4.05; p < 0.001), CV (β = 0.67; CI 95% 0.57 to 0.77; p < 0.001) and adherence to sensor usage (β = −0.16; CI 95% −1.27 to −0.06; p < 0.002). Conclusions LADA present better control according to some glucometric parameters and a low GRI. However, the type of DM is not a factor that is independently associated with GRI.
- 4 November 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 159 (11) , 522-528
Prevalence of autoimmune diseases in patients with type 1 diabetes mellitus. DIACAM 1 study 2010–2020
- 4 November 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 159 (11) , 522-528
Prevalence of autoimmune diseases in patients with type 1 diabetes mellitus. DIACAM 1 study 2010–2020
- 24 March 2022
- Published by Elsevier in Medicina Clinica
- Vol. 159 (11) , 522-528
Prevalencia de enfermedades autoinmunes en pacientes con diabetes mellitus tipo 1. Estudio DIACAM 1 2010-2020
- 24 March 2022
- Published by Elsevier in Medicina Clinica
- Vol. 159 (11) , 522-528
Prevalencia de enfermedades autoinmunes en pacientes con diabetes mellitus tipo 1. Estudio DIACAM 1 2010-2020